Shots:
- Royalty Pharma acquiring Revolution Medicines’ royalties for daraxonrasib (P-III RASolute 302), providing up to $1.25B across five $250M milestone tranches, plus an additional $750M debt facility in three tranches
- Revolution received the $250M upfront, with future payments tied to P-III data (2026), FDA approval (by Jan 2028), and sales milestones, allowing access to further synthetic royalty and debt financing
- In return, Royalty Pharma will obtain 15-year capped royalties (on $8B annual sales), ranging from 2.26% if only two tranches are drawn, up to 4.29% if all five are received, aligning incentives between both parties
Ref: Revolution Medicines| Image: Royalty Pharma and Revolution Medicines| Press Release
Related News:- Xcell Biosciences and ThermoFisher Enter Into a Joint Research Collaboration to Advance Cell Therapies
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
